FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1734-1736 October 20, 2005 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Piccart-Gebhart, M. J. Related Article by Romond, E. H. PubMed Citation

Two articles in this issue of the Journal report on the considerable therapeutic benefit of trastuzumab, a monoclonal antibody, in primary breast cancer, as measured by reductions in the rates of both recurrence and death.^1,2 These reports, which complete the bench-to-bedside cycle, are elegant examples of translational research. The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases and is normally involved in the regulation of cell proliferation. The HER2 gene, located on the short arm of chromosome 17, was discovered and cloned in 1983 and found . . . [Full Text of this Article]

Source Information

From the Department of Breast Medical Oncology, the University of Texas M.D. Anderson Cancer Center, Houston.

Related Letters:

Trastuzumab in Breast Cancer
Gilbert S. G., Banna G. L., Santoro A., Gounaris I. G., Katsumata M., Drebin J. A., Greene M. I., Mastrianni D. M., Mano M., Cameron D., Gelber R. D., the HERA Trial Study Team , Bryant J., Romond E., Perez E. A., Hortobagyi G. N., Barron H.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:640-644, Feb 9, 2006. Correspondence

This article has been cited by other articles:

• Goodwin, P. J. (2008). Host-Related Factors in Breast Cancer: An Underappreciated Piece of the Puzzle?. JCO 26: 3299-3300 [Full Text]  
• Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., Murray, S. (2008). Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Oncologist 13: 620-630 [Abstract] [Full Text]  
• Petrelli, F., Cabiddu, M., Cazzaniga, M. E., Cremonesi, M., Barni, S. (2008). Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era. The Oncologist 13: 373-381 [Abstract] [Full Text]  
• Tot, T. (2007). The Theory of the Sick Breast Lobe and the Possible Consequences. INT J SURG PATHOL 15: 369-375 [Abstract]  
• Kroese, M., Zimmern, R. L, Pinder, S. E (2007). HER2 status in breast cancer--an example of pharmacogenetic testing. JRSM 100: 326-329 [Abstract] [Full Text]  
• Spano, L. J. (2007). A terrible beauty: A physician's story of ovarian cancer. cfp 53: 983-985 [Full Text]  
• Kunz, C., Borghouts, C., Buerger, C., Groner, B. (2006). Peptide Aptamers with Binding Specificity for the Intracellular Domain of the ErbB2 Receptor Interfere with AKT Signaling and Sensitize Breast Cancer Cells to Taxol. Mol Cancer Res 4: 983-998 [Abstract] [Full Text]  
• Guarneri, V., Lenihan, D. J., Valero, V., Durand, J.-B., Broglio, K., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobagyi, G. N., Esteva, F. J. (2006). Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. JCO 24: 4107-4115 [Abstract] [Full Text]  
• Ambrosino, E., Spadaro, M., Iezzi, M., Curcio, C., Forni, G., Musiani, P., Wei, W.-Z., Cavallo, F. (2006). Immunosurveillance of erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.. Cancer Res. 66: 7734-7740 [Abstract] [Full Text]  
• Bunn, P. A. Jr., Dziadziuszko, R., Varella-Garcia, M., Franklin, W. A., Witta, S. E., Kelly, K., Hirsch, F. R. (2006). Biological Markers for Non-Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.. Clin. Cancer Res. 12: 3652-3656 [Full Text]  
• Piccart-Gebhart, M. J. (2006). Anthracyclines and the Tailoring of Treatment for Early Breast Cancer. NEJM 354: 2177-2179 [Full Text]  
• Hemminki, A., Kellokumpu-Lehtinen, P.-L. (2006). Harmful impact of EU clinical trials directive.. BMJ 332: 501-502 [Full Text]  
• Gilbert, S. G., Banna, G. L., Santoro, A., Gounaris, I. G., Katsumata, M., Drebin, J. A., Greene, M. I., Mastrianni, D. M., Mano, M., Cameron, D., Gelber, R. D., the HERA Trial Study Team, , Bryant, J., Romond, E., Perez, E. A., Hortobagyi, G. N., Barron, H. (2006). Trastuzumab in breast cancer.. NEJM 354: 640-644 [Full Text]  
• Dent, R., Clemons, M. (2005). Adjuvant trastuzumab for breast cancer. BMJ 331: 1035-1036 [Full Text]  
• (2005). Trastuzumab for HER2-Positive Breast Cancer: A Major Step Forward. JWatch Women's Health 2005: 1-1 [Full Text]  
• (2005). Trastuzumab for HER2-Positive Breast Cancer. JWatch Gastroenterology 2005: 12-12 [Full Text]  
• (2005). Trastuzumab for HER2-Positive Breast Cancer. JWatch General 2005: 1-1 [Full Text]